-+ 0.00%
-+ 0.00%
-+ 0.00%

Moleculin nears MIRACLE trial unblinding for Annamycin in relapsed AML by June 30

PUBT·05/13/2026 12:02:11
Listen to the news
Moleculin nears MIRACLE trial unblinding for Annamycin in relapsed AML by June 30
  • Moleculin Biotech flagged late Q2 2026 unblinding for first 45 patients in pivotal MIRACLE trial testing Annamycin with cytarabine in relapsed or refractory acute myeloid leukemia, with results expected before June 30, 2026.
  • Blinded interim data showed remission outcomes tracking well above historical experience for cytarabine alone, signaling potential added benefit without disclosing arm-level performance.
  • Safety readout remained consistent with no cardiotoxicity observed to date, supporting continued development focus for Annamycin in this setting.
  • Enrollment continued toward 90 patients for Part A in Q3 2026, keeping timeline intact for a second unblinding later in 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moleculin Biotech Inc. published the original content used to generate this news brief on May 13, 2026, and is solely responsible for the information contained therein.